Premium
Immunotherapy and systemic chemotherapy for the treatment of intraocular lymphoma. Indications and results
Author(s) -
Soussain Carole
Publication year - 2019
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2019.8279
Subject(s) - medicine , intraocular lymphoma , primary central nervous system lymphoma , chemotherapy , lymphoma , oncology , immunotherapy , refractory (planetary science) , cancer , physics , astrobiology
Primary vitreo‐retinal lymphoma (PVRL), which is part of the primary central nervous system lymphoma (PCNSL) group, is a rare presentation with a dismal prognosis. In addition to the functional prognosis on the vision, PVRL are at high risk of dissemination in the CNS. The therapeutic management of PVRL remains controversial, ranging from local treatment, systemic chemotherapy and even intensive chemotherapy with autologous stem cell transplantation. Targeted therapies have recently shown encouraging result in relapse or refractory PVRL. We will review the different options for systemic treatments of PVRL in front‐line and at relapse and highlight the needs for improving the outcome of patients with PVRL. Although intra‐ocular (IO) involvement of PCNSL does not appear to worsen the prognosis of PCNSL, the management of IO involvement is still controversial and suboptimal.